Viking Therapeutics, Inc.
US ˙ NasdaqCM ˙ US92686J1060

SecurityVKTX / Viking Therapeutics, Inc.
InstitutionAdvisor Group Holdings, Inc.
Latest Disclosed Ownership76,987 shares
Latest Disclosed Value $ 2,505,136
Advisor Group Holdings, Inc. ownership in VKTX / Viking Therapeutics, Inc.

On May 15, 2026 - Advisor Group Holdings, Inc. filed a 13F-HR form disclosing ownership of 76,987 shares of Viking Therapeutics, Inc. (US:VKTX) valued at $2,505,157 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 59,774 shares of Viking Therapeutics, Inc.. This represents a change in shares of 28.80% during the quarter. The current value of the position is $2,258,029 USD.

Advisor Group Holdings, Inc. has a history of taking positions in derivatives of the underlying security (VKTX) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

VKTX / Viking Therapeutics, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F VIKING THERAPEUTICS COM 92686J106 76,987 17,213 28.80 2,505 19.17 0.0021
2026-02-17 2025-12-31 13F VIKING THERAPEUTICS COM 92686J106 59,774 -18,848 -23.97 2,103 -0.38 0.0031
2025-11-14 2025-09-30 13F VIKING THERAPEUTICS COM 92686J106 78,622 2,970 3.93 2,110 5.34 0.0030
2025-09-04 2025-06-30 13F/A-1 IKING THERAPEUTICS COM 92686J106 75,652 -4,407 -5.50 2,003 3.62 0.0036
2025-08-13 2025-06-30 13F IKING THERAPEUTICS COM 92686J106 69,426 -10,633 2,579 0.0030
2025-05-12 2025-03-31 13F VIKING THERAPEUTICS COM 92686J106 80,059 24,775 44.81 1,933 -13.08 0.0043
2025-06-06 2024-12-31 13F/A-1 VIKING THERAPEUTICS COM 92686J106 55,284 19,091 52.75 2,224 -2.92 0.0050
2025-02-07 2024-12-31 13F VIKING THERAPEUTICS COM 92686J106 18,465 -17,728 1,138 0.0029
2024-11-13 2024-09-30 13F VIKING THERAPEUTICS COM 92686J106 36,193 8,002 28.38 2,291 53.35 0.0052
2024-08-13 2024-06-30 13F VIKING THERAPEUTICS COM 92686J106 28,191 -2,735 -8.84 1,494 -41.07 0.0035
2024-05-10 2024-03-31 13F VIKING THERAPEUTICS COM 92686J106 30,926 1,040 3.48 2,536 355.94 0.0057
2024-02-12 2023-12-31 13F VIKING THERAPEUTICS COM 92686J106 29,886 -193,409 -86.62 556 -77.50 0.0010
2023-11-13 2023-09-30 13F VIKING THERAPEUTICS COM 92686J106 223,295 114,863 105.93 2,472 40.64 0.0037
2023-08-21 2023-06-30 13F/A-1 VIKING THERAPEUTICS COM 92686J106 108,432 -18,939 -14.87 1,757 -17.12 0.0032
2023-08-10 2023-06-30 13F VIKING THERAPEUTICS COM 92686J106 108,432 -18,939 1,757 0.0005
2023-05-12 2023-03-31 13F VIKING THERAPEUTICS COM 92686J106 127,371 -20,533 -13.88 2,121 52.63 0.0040
2023-02-10 2022-12-31 13F VIKING THERAPEUTICS COM 92686J106 147,904 1,466 1.00 1,390 248.12 0.0028
2022-11-14 2022-09-30 13F VIKING THERAPEUTICS COM 92686J106 146,438 5,187 3.67 399 -2.21 0.0009
2022-08-10 2022-06-30 13F VIKING THERAPEUTICS COM 92686J106 141,251 31,887 29.16 408 -56.08 0.0009
2022-05-04 2022-03-31 13F VIKING THERAPEUTICS COM 92686J106 109,364 20,228 22.69 929 126.59 0.0018
2022-02-03 2021-12-31 13F VIKING THERAPEUTICS COM 92686J106 89,136 9,171 11.47 410 -18.33 0.0008
2021-11-05 2021-09-30 13F VIKING THERAPEUTICS COM 92686J106 79,965 2,200 2.83 502 7.73 0.0010
2021-08-02 2021-06-30 13F VIKING THERAPEUTICS COM 92686J106 77,765 5,320 7.34 466 1.75 0.0010
2021-05-13 2021-03-31 13F VIKING THERAPEUTICS COM 92686J106 72,445 -2,770 -3.68 458 8.27 0.0011
2021-02-10 2020-12-31 13F VIKING THERAPEUTICS COM 92686J106 75,215 2,930 4.05 423 0.24 0.0011
2020-11-12 2020-09-30 13F VIKING THERAPEUTICS COM 92686J106 72,285 11,387 18.70 422 -3.87 0.0013
2020-08-14 2020-06-30 13F VIKING THERAPEUTICS COM 92686J106 60,898 17,077 38.97 439 115.20 0.0015
2020-05-18 2020-03-31 13F VIKING THERAPEUTICS COM 92686J106 43,821 43,821 204 0.0008
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2026-02-17 2025-12-31 13F VIKING THERAPEUTICS CALL Call 0 -100.00 0 -100.00 n/a n/a n/a
2025-11-14 2025-09-30 13F VIKING THERAPEUTICS CALL Call 8 60.00 2 n/a n/a n/a
2025-09-04 2025-06-30 13F/A VIKING THERAPEUTICS CALL Call 5 -76.19 1 -100.00 n/a n/a n/a
2025-08-13 2025-06-30 13F VIKING THERAPEUTICS CALL Call 5 10 n/a n/a n/a
2025-05-12 2025-03-31 13F VIKING THERAPEUTICS CALL Call 21 320.00 19 111.11 n/a n/a n/a
2025-06-06 2024-12-31 13F/A VIKING THERAPEUTICS CALL Call 5 150.00 10 -10.00 n/a n/a n/a
2025-02-07 2024-12-31 13F VIKING THERAPEUTICS CALL Call 2 11 n/a n/a n/a
2024-11-13 2024-09-30 13F VIKING THERAPEUTICS CALL Call 2 0.00 11 25.00 n/a n/a n/a
2024-08-13 2024-06-30 13F VIKING THERAPEUTICS CALL Call 2 0.00 8 -42.86 n/a n/a n/a
2024-05-10 2024-03-31 13F VIKING THERAPEUTICS CALL Call 2 0.00 14 600.00 n/a n/a n/a
2024-02-12 2023-12-31 13F VIKING THERAPEUTICS INC CALL COM Call 2 0.00 2 n/a n/a n/a
2023-11-13 2023-09-30 13F VIKING THERAPEUTICS INC CALL COM Call 2 0.00 1 -100.00 n/a n/a n/a
2023-08-21 2023-06-30 13F/A VIKING THERAPEUTICS INC CALL COM Call 2 2 n/a n/a n/a
2023-08-10 2023-06-30 13F VIKING THERAPEUTICS INC CALL COM Call 2 2 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.